歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01672 歌礼制药-B

已收盘 02-10 16:09:14

17.140

+0.840

+5.15%

最高17.400	最低16.300	成交量508.85万
今开16.300	昨收16.300	日振幅6.75%
总市值170.03亿	流通市值170.03亿	总股本9.92亿
成交额8,694万	换手率0.51%	流通股本9.92亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01672","market":"HK","secType":"STK","nameCN":"歌礼制药-B","latestPrice":17.14,"timestamp":1770710954003,"preClose":16.3,"halted":0,"volume":5088511,"delay":0,"changeRate":0.05153374233128833,"floatShares":992000000,"shares":992000000,"eps":-0.33992543831204364,"marketStatus":"已收盘","change":0.84,"latestTime":"02-10 16:09:14","open":16.3,"high":17.4,"low":16.3,"amount":86941544,"amplitude":0.067485,"askPrice":17.15,"askSize":1000,"bidPrice":17.06,"bidSize":6000,"shortable":3,"etf":0,"ttmEps":-0.3001435114291968,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1770773400000},"marketStatusCode":5,"adr":0,"listingDate":1533052800000,"exchange":"SEHK","adjPreClose":16.3,"openAndCloseTimeList":[[1770687000000,1770696000000],[1770699600000,1770710400000]],"volumeRatio":1.151088,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01672","defaultTab":"news","newsList":[{"id":"1115224330","title":"歌礼制药（1672）更新翌日披露报表，已发行股本增至约10.61亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=1115224330","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1115224330?lang=zh_cn&edition=full","pubTime":"2026-02-10 18:16","pubTimestamp":1770718565,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年2月10日发布翌日披露报表，披露新股发行及回购股份拟注销等事项。公告显示，公司在2026年2月10日根据一般授权配发及发行69,256,000股新股份，占期初已发行股本约6.98%，每股发行价为12.18港元。发行完成后，公司已发行股本由991,874,320股增至1,061,130,320股，库藏股维持7,084,210股，总股本变动为1,068,214,530股。此外，公司披露2025年4月至12月期间多次回购股份，累计回购5,786,000股，价格区间介乎每股4.8531港元至14.5794港元，上述股份暂未注销。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"gpt_icon":0},{"id":"2610648244","title":"歌礼制药-B(01672)完成配售6925.6万股股份 净筹约8.35亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610648244","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610648244?lang=zh_cn&edition=full","pubTime":"2026-02-10 17:32","pubTimestamp":1770715961,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)公布，已于2026年2月10日完成配售合共6925.6万股股份，每股配售价12.18港元，净筹约8.35亿港元，约90%建议用于治疗肥胖症的小分子口服GLP-1受体激动剂ASC30的全球III期临床试验的准备、基础工作及启动，约10%建议用作营运资金及其他一般公司用途。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1403717.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","01477","BK1191","01672","BK1515","BK1161"],"gpt_icon":0},{"id":"2610003646","title":"每日卖空追踪 | 歌礼制药-B 02月10日卖空量成交20.9万股，卖空比例为4.11%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610003646","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610003646?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:30","pubTimestamp":1770712225,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间02月10日，涨5.15%，卖空量成交20.9万股，较上一交易日减少7.93%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163313a492b9a7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210163313a492b9a7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","01477","BK1191","BK1515","01672","BK1161"],"gpt_icon":0},{"id":"2610649887","title":"歌礼制药-B02月10日获主力加仓1393.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2610649887","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610649887?lang=zh_cn&edition=full","pubTime":"2026-02-10 16:15","pubTimestamp":1770711339,"startTime":"0","endTime":"0","summary":"02月10日, 歌礼制药-B股价涨5.15%，报收17.14元，成交金额8694.2万元，换手率0.51%，振幅6.75%，量比1.15。歌礼制药-B今日主力资金净流入1393.0万元，连续7日净流入，上一交易日主力净流入51.3万元。该股近5个交易日上涨31.57%，主力资金累计净流入2449.9万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入2943.0万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210161831a6e99934&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210161831a6e99934&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01672","01477","BK1574","BK1515","BK1191","BK1161"],"gpt_icon":0},{"id":"2610884649","title":"歌礼制药-B再涨超6% ASC30加速全球III期临床 机构称BD潜力较大","url":"https://stock-news.laohu8.com/highlight/detail?id=2610884649","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610884649?lang=zh_cn&edition=full","pubTime":"2026-02-10 14:52","pubTimestamp":1770706348,"startTime":"0","endTime":"0","summary":"歌礼制药-B再涨超6%，截至发稿，涨5.52%，报17.2港元，成交额6945.8万港元。消息面上，GIC在歌礼制药最新一轮配售中获得头部分配额度，将助力ASC30加速全球III期临床推进。交易完成后，GIC持有歌礼制药6.42%股权。东方证券表示，ASC30减重数据优越，安全性良好，且分子专利已获美国授权，BD潜力较大。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210150504a49257bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260210150504a49257bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01477","01672","BK1515","BK1191","BK1574","BK1161"],"gpt_icon":0},{"id":"1116933064","title":"港股异动 | 歌礼制药盘中涨超8%，GIC斥资7.81亿港元增持歌礼制药，持股比例已达6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=1116933064","media":"老虎资讯综合","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116933064?lang=zh_cn&edition=full","pubTime":"2026-02-09 10:01","pubTimestamp":1770602515,"startTime":"0","endTime":"0","summary":"2月9日，$歌礼制药-B$盘中涨超8%，GIC斥资7.81亿港元增持歌礼制药，持股比例已达6.42%。消息面上，2月6日，$港交所$披露的信息显示，新加坡政府投资基金以每股均价12.18港元的价格，斥资约7.81亿港元买入歌礼制药6412.8万股新股。交易完成后，GIC持有歌礼制药6.42%股权。公开资料显示，此次入股源于歌礼制药近期完成对配股计划。GIC在此轮配售中获得头部分配额度。","market":"hk","thumbnail":"https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/df4ec61541b268a5353585001973d7cb"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8173ebb445828bbdab4a68b6f572d4e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4104","01672","BK1191","BK1515","01477","BK1161","BK4585","BK4588","BK1574"],"gpt_icon":0},{"id":"2610501497","title":"港股异动 | 歌礼制药-B(01672)早盘涨近9% GIC斥资7.81亿港元增持歌礼制药 持股比例已达6.42%","url":"https://stock-news.laohu8.com/highlight/detail?id=2610501497","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2610501497?lang=zh_cn&edition=full","pubTime":"2026-02-09 09:43","pubTimestamp":1770601432,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B早盘涨近9%，截至发稿，涨8.29%，报16.46港元，成交额1428.9万港元。消息面上，2月6日，港交所披露的信息显示，新加坡政府投资基金以每股均价12.18港元的价格，斥资约7.81亿港元买入歌礼制药6412.8万股新股。交易完成后，GIC持有歌礼制药6.42%股权。公开资料显示，此次入股源于歌礼制药近期完成对配股计划。GIC在此轮配售中获得头部分配额度。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8173ebb445828bbdab4a68b6f572d4e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1402978.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01672","01477","BK4104","BK4588","BK1191","VXUS","BK1515","BK1574","GIC","BK4585","BK1161","VT"],"gpt_icon":0},{"id":"2609596974","title":"歌礼制药-B(01672.HK)获GIC Private Limited增持6412.8万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2609596974","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609596974?lang=zh_cn&edition=full","pubTime":"2026-02-06 21:17","pubTimestamp":1770383821,"startTime":"0","endTime":"0","summary":"格隆汇2月6日丨根据联交所最新权益披露资料显示，2026年2月3日，歌礼制药-B(01672.HK)获GIC Private Limited在场内以每股均价12.18港元增持6412.8万股，涉资约7.81亿港元。\r\n\r\n　　增持后，GIC Private Limited最新持股数目为6412.8万股，持股比例为6.42%。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202602/06/20260206499677.jpg","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202602/06/20260206499677.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260206/32004708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1515","BK4104","01477","BK1191","BK1574","01672","GIC","BK1161"],"gpt_icon":0},{"id":"2609273347","title":"东方证券：替尔泊肽加冕新“药王” 未来减重药物商业价值将快速释放","url":"https://stock-news.laohu8.com/highlight/detail?id=2609273347","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609273347?lang=zh_cn&edition=full","pubTime":"2026-02-05 13:38","pubTimestamp":1770269908,"startTime":"0","endTime":"0","summary":"当前，MNC已将减重视为核心的战略要地，大额BD和并购频现，今年催化密集。东方证券主要观点如下：替尔泊肽加冕“药王”，减重药物将霸榜2026年2月4日，礼来发布2025年业绩，替尔泊肽全年销售365.07亿美元，加冕2025年全球“药王”，并有望多年蝉联。据Evaluate预测，到2030年全球销售额前十药物中约半数为GLP-1类药物。减重BD未停，新方向需求将起去年末以来，减重领域交易仍在持续。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1401960.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03958","SG9999004220.SGD","LU0072913022.USD","LU1807302812.USD","LU1226287529.USD","LU1226288170.HKD","IE00B5MMRT66.SGD","IE00B031HY20.USD","LU1960683339.HKD","600958","LU0314109678.HKD","IE0008369823.USD","LU2039709279.SGD","01672","LU1152091754.HKD","LU1813983027.USD","IE0008368742.USD","IE00B543WZ88.USD","LU0326950275.SGD","LU0140636845.USD","LU1008478684.HKD","01093","LU1226288253.USD","LU1951186391.HKD","BK1147","LU0880133367.SGD","BK1161","LU1993786604.SGD","BK1574","BK0188","BK0012","BK1564","LU0501845795.SGD","LU1328277881.USD","BK1191","BK1515","BK0028","LU1226287875.USD","LU0315179316.USD","LU1226287792.SGD","IE00BZ08YT58.USD","LU1152091168.USD","IE00BZ08YS42.EUR","BK0183","LU0067412154.USD","IE00BZ08YR35.GBP","BK1521","BK0276","HK0000165453.HKD"],"gpt_icon":0},{"id":"2609301751","title":"歌礼制药-B盘中异动 股价大跌5.30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2609301751","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2609301751?lang=zh_cn&edition=full","pubTime":"2026-02-05 10:59","pubTimestamp":1770260396,"startTime":"0","endTime":"0","summary":"2026年02月05日早盘10时59分，歌礼制药-B股票出现波动，股价大幅下跌5.30%。截至发稿，该股报13.220港元/股，成交量84.7万股，换手率0.09%，振幅7.02%。机构评级方面，在所有1家参与评级的机构中，100%的券商给予持有建议，无券商给予买入、卖出建议。歌礼制药-B股票所在的生物技术行业中，整体跌幅为0.71%。其相关个股中，银诺医药-B、药捷安康-B、中生北控生物科技涨幅较大，振幅较大的相关个股有银诺医药-B、北海康成-B、MIRXES-B，振幅分别为20.06%、16.50%、10.94%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205105957a6d52827&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260205105957a6d52827&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","01672","BK1515","BK1574","BK1161","01477"],"gpt_icon":0},{"id":"1166254163","title":"歌礼制药（01672）2026年1月股份变动月报表，股本维持不变","url":"https://stock-news.laohu8.com/highlight/detail?id=1166254163","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1166254163?lang=zh_cn&edition=full","pubTime":"2026-02-03 19:01","pubTimestamp":1770116464,"startTime":"0","endTime":"0","summary":"歌礼制药有限公司于2026年2月3日披露2026年1月股份变动月报表，报告期截至2026年1月31日。公告显示，公司注册股本维持在7,000,000,000股，每股面值USD 0.0001，总注册资本USD 700,000。截至本月末，已发行股份总数为991,874,320股，库存股份数为7,084,210股，两者合计998,958,530股，均与上月保持一致。同时，此前于2025年回购的多批普通股仍处于拟注销状态，截至2026年1月31日尚未注销，未对本期股份数量构成影响。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01672"],"gpt_icon":0},{"id":"2608876023","title":"每日卖空追踪 | 歌礼制药-B 02月03日卖空量成交46.8万股，卖空比例为13.36%","url":"https://stock-news.laohu8.com/highlight/detail?id=2608876023","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608876023?lang=zh_cn&edition=full","pubTime":"2026-02-03 16:30","pubTimestamp":1770107423,"startTime":"0","endTime":"0","summary":"歌礼制药-B北京时间02月03日，涨3.07%，卖空量成交46.8万股，较上一交易日减少57.3%更多个股卖空数据请看下面视窗：卖空数据是观测市场多空博弈的关键指标：短期可反映市场情绪，高卖空比例预示看空预期，但极端值可能触发轧空反弹；长期结合基本面恶化则预警下行风险。需注意其局限性：卖空行为包含对冲需求，未必单纯看空；机构可能通过衍生品做空未体现在数据中，且散户跟风易扭曲信号。股市有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203163357a6cdb6f5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203163357a6cdb6f5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","01672","BK1161","01477","BK1191"],"gpt_icon":0},{"id":"2608845081","title":"歌礼制药配售价较前收盘每股12.69港元折让4.0%。","url":"https://stock-news.laohu8.com/highlight/detail?id=2608845081","media":"新浪财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608845081?lang=zh_cn&edition=full","pubTime":"2026-02-03 07:44","pubTimestamp":1770075895,"startTime":"0","endTime":"0","summary":"来源：滚动播报歌礼制药配售价较前收盘每股12.69港元折让4.0%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203074752a474e148&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260203074752a474e148&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1515","01672","BK1161","BK1191","01477"],"gpt_icon":0},{"id":"2608816051","title":"歌礼制药-B(01672)拟折让约4%配售6925.6万股 净筹约8.353亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2608816051","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2608816051?lang=zh_cn&edition=full","pubTime":"2026-02-03 07:38","pubTimestamp":1770075525,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B(01672)发布公告，于2026年2月3日，公司拟配售6925.6万股，占公司于本公告日期已发行股份数目(即9.92亿股股份，不包括708.42万股库存股份)约6.98%。每股配售股份的配售价12.18港元，较2月2日收市价每股股份12.69港元折让约4.0%。配售所得款项总额预期合共约为8.435亿港元，而配售所得款项净额预期合共约为8.353亿港元。配售事项所得款项净额中约90%建议用于治疗肥胖症的小分子口服GLP-1受体激动剂ASC30的全球III期临床试验的准备、基础工作及启动，而配售事项所得款项净额中约10%建议用作营运资金及其他一般公司用途。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1400799.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1191","BK1161","01672","01477","BK1515","BK1574"],"gpt_icon":0},{"id":"1113366256","title":"歌礼制药公布III期开放标签研究积极顶线结果：首创每日一次口服FASN抑制剂denifanstat治疗痤疮","url":"https://stock-news.laohu8.com/highlight/detail?id=1113366256","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1113366256?lang=zh_cn&edition=full","pubTime":"2026-01-29 19:02","pubTimestamp":1769684546,"startTime":"0","endTime":"0","summary":"歌礼制药宣布，其针对痤疮治疗的首创、每日一次口服脂肪酸合成酶抑制剂denifanstat（研发代号：ASC40）的III期开放标签研究，已获得积极的顶线结果。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1515","BK1574","BK1161","01672"],"gpt_icon":0},{"id":"2607790083","title":"歌礼制药-B(01672)：同类首创每日一次口服FASN抑制剂地尼法司他(ASC40)治疗痤疮的III期开放标签研究取得积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=2607790083","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607790083?lang=zh_cn&edition=full","pubTime":"2026-01-29 18:56","pubTimestamp":1769684198,"startTime":"0","endTime":"0","summary":"智通财经APP讯，歌礼制药-B 发布公告，同类首创、每日一次口服小分子脂肪酸合成酶抑制剂地尼法司他在中重度寻常性痤疮患者中的III期开放标签研究取得积极顶线结果。这240例患者均接受了40周的每日一次地尼法司他治疗，且此前均接受过12周的地尼法司他或安慰剂治疗。地尼法司他 显示出良好的安全性和耐受性特征。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399288.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","01672","BK1574","BK4134","BK1191","BK1515","BK1161","III"],"gpt_icon":0},{"id":"1187238733","title":"歌礼制药-B公布denifanstat（ASC40）三期开放标签研究积极顶线结果","url":"https://stock-news.laohu8.com/highlight/detail?id=1187238733","media":"美股速递","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1187238733?lang=zh_cn&edition=full","pubTime":"2026-01-29 18:52","pubTimestamp":1769683934,"startTime":"0","endTime":"0","summary":"歌礼制药-B宣布其候选药物denifanstat（研发代号ASC40）在三期开放标签临床研究中取得积极的顶线数据。该研究结果标志着公司在非酒精性脂肪性肝炎治疗领域的研发进程取得重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01672","BK1515"],"gpt_icon":0},{"id":"2607099336","title":"歌礼制药-B01月29日主力净流入121.0万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2607099336","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607099336?lang=zh_cn&edition=full","pubTime":"2026-01-29 16:16","pubTimestamp":1769674562,"startTime":"0","endTime":"0","summary":"01月29日, 歌礼制药-B股价涨2.49%，报收13.58元，成交金额1722.9万元，换手率0.13%，振幅5.28%，量比0.64。歌礼制药-B今日主力资金净流入121.0万元，上一交易日主力净流出51.0万元。该股近5个交易日上涨1.87%，主力资金累计净流入860.1万元；近20日主力资金累计净流入844.7万元，其中净流入天数为8日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129162533a463da71&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260129162533a463da71&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","01477","01672","BK1191","BK1161","BK1574"],"gpt_icon":0},{"id":"2607770678","title":"港股异动 | 歌礼制药-B(01672)午后涨超4% 公司启动糖尿病药物ASC30 II期临床试验患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2607770678","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607770678?lang=zh_cn&edition=full","pubTime":"2026-01-29 14:24","pubTimestamp":1769667887,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，歌礼制药-B午后涨超4%，截至发稿，涨3.85%，报13.76港元，成交额1218.55万港元。消息面上，歌礼制药发布公告，其口服小分子胰高血糖素样肽-1受体激动剂ASC30用于治疗2型糖尿病的美国II期临床试验已完成首例患者给药。计划在美国多中心招募约100名2型糖尿病患者。歌礼制药创始人、董事长兼首席执行官吴劲梓博士表示：\"将ASC30的临床开发扩展至庞大的糖尿病治疗市场，是符合逻辑的下一步。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1399045.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["01477","BK1161","BK1191","01672","BK1515","BK1574","VT","BK4585","BK4588"],"gpt_icon":0},{"id":"2607135772","title":"恒瑞医药、歌礼制药等国产口服GLP-1药物突破在即，赛道将迎来新竞局","url":"https://stock-news.laohu8.com/highlight/detail?id=2607135772","media":"制药网","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2607135772?lang=zh_cn&edition=full","pubTime":"2026-01-28 16:40","pubTimestamp":1769589631,"startTime":"0","endTime":"0","summary":"目前，全球范围内尚无口服小分子GLP-1R激动剂上市。除了恒瑞医药外，歌礼制药于1月26日也发布公告称，迎来新进展，公司完成了口服小分子GLP-1R激动剂ASC30治疗糖尿病的美国II期研究头批受试者给药。随着临床数据的逐步完善，国产口服GLP-1药物有望为患者提供更可及的治疗选择。未来，随着更多临床数据落地，国产口服GLP-1药物有望在市场中占据重要地位，开启创新治疗的新时代。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128173807a45fb98e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20260128173807a45fb98e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["LU0359201612.USD","LU1023057109.AUD","01672","LU0359201885.HKD","BK1191","BK1515","LU0359202008.SGD","01477","BK1161","01276","LU2543165471.USD","BK1574"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.ascletis.com","stockEarnings":[{"period":"1week","weight":0.2845},{"period":"1month","weight":0.2947},{"period":"3month","weight":0.4645},{"period":"6month","weight":0.0349},{"period":"1year","weight":2.8902},{"period":"ytd","weight":0.4311}],"compareEarnings":[{"period":"1week","weight":0.0094},{"period":"1month","weight":0.0303},{"period":"3month","weight":0.0124},{"period":"6month","weight":0.0552},{"period":"1year","weight":0.2789},{"period":"ytd","weight":0.0545}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"歌礼制药有限公司是一家主要从事医药产品研发、生产和销售的投资控股公司。该公司专注于病毒性疾病、非酒精性脂肪性肝炎（NASH）或原发性胆汁性胆管炎（PBC）及肿瘤领域。该公司的产品管线包括用于慢性乙肝功能性治愈的ASC22、用于呼吸道合胞病毒（RSV）的ASC10、用于人类免疫缺陷病毒（HIV）功能性治愈的ASC22、用於新冠肺炎的ASC10及ASC11、用於NASH的ASC41、用於PBC的ASC42、用于实体瘤的ASC61、用于中、重度痤疮的ASC40等。该公司在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.75,"avgChangeRate":0.146882},{"month":2,"riseRate":0.75,"avgChangeRate":0.10495},{"month":3,"riseRate":0.285714,"avgChangeRate":-0.058802},{"month":4,"riseRate":0.428571,"avgChangeRate":-0.059274},{"month":5,"riseRate":0.428571,"avgChangeRate":0.007612},{"month":6,"riseRate":0.428571,"avgChangeRate":-0.024499},{"month":7,"riseRate":0.571429,"avgChangeRate":0.032162},{"month":8,"riseRate":0.285714,"avgChangeRate":-0.037953},{"month":9,"riseRate":0.125,"avgChangeRate":-0.072967},{"month":10,"riseRate":0.5,"avgChangeRate":-0.023171},{"month":11,"riseRate":0.875,"avgChangeRate":0.185422},{"month":12,"riseRate":0.5,"avgChangeRate":0.087327}],"exchange":"SEHK","name":"歌礼制药-B","nameEN":"ASCLETIS-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"歌礼制药-B,01672,歌礼制药-B股票,歌礼制药-B股票老虎,歌礼制药-B股票老虎国际,歌礼制药-B行情,歌礼制药-B股票行情,歌礼制药-B股价,歌礼制药-B股市,歌礼制药-B股票价格,歌礼制药-B股票交易,歌礼制药-B股票购买,歌礼制药-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"歌礼制药-B(01672)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供歌礼制药-B(01672)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}